Clinical trials: Partial Seizures
Epilepsy, Partial-onset Seizures
Study to Evaluate the Safety, Tolerability, and Efficacy of Long-term Adjunctive Therapy With Lacosamide in Adults With Partial-onset Seizures
The purpose of this trial is to evaluate the safety and tolerability of long-term administration of Lacosamide at doses up to 400 mg/day in Japanese and Chinese adults with Epilepsy who have completed the Treatment and Transition…
- Trial name
- NCT01832038
- Testing
- Lacosamide
- Where
- 67 sites in China, Japan
- Volunteers
- 473 people
- Sponsor
- UCB Pharma SA
Epilepsy
Study in Pediatric Subjects With Epilepsy
This is an open-label study to evaluate the pharmacokinetics, safety and tolerability of ezogabine/retigabine in subjects aged 12 years to less than 18 years with uncontrolled partial onset seizures or Lennos-Gastaut syndrome.
- Trial name
- NCT01494584
- Testing
- ezogabine/retigabine
- Where
- 4 sites in United States
- Volunteers
- 5 people
- Sponsor
- GlaxoSmithKline
Epilepsy, Partial Seizures
A Study of the Efficacy and Safety of Pregabalin as Add-On Therapy for Partial Onset Seizures in Children Ages 4-16 Years
Study A0081041 is a double blind, placebo controlled, randomized, parallel group, multicenter study to evaluate the safety and efficacy of two dose levels of pregabalin administered in equally divided daily doses, in either…
- Trial name
- PERIWINKLE (NCT01389596)
- Testing
- Pregabalin add-on therapy
- Where
- 86 sites in United States, Belgium and 16 more
- Volunteers
- 295 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Partial Epilepsies, Partial Onset Seizures
Study to Assess the Long-term Safety of Oral Lacosamide in Subjects With Partial-onset Seizures
The purpose of this study is to allow eligible subjects from the parent study, SP925 [NCT00655551] to continue lacosamide and to obtain additional long-term safety data
- Trial name
- NCT00655486
- Testing
- lacosamide
- Where
- 7 sites in United States
- Volunteers
- 97 people
- Sponsor
- UCB BIOSCIENCES, Inc.
Healthy
A Study to Assess if Epanutin Infatabs 50 mg From Germany Are Similar to Dilantin Infatabs 50 mg From Australia
In this study, the bioequivalence of Epanutin Infatabs® 50 mg (sourced from Germany) and Dilantin Infatabs® 50 mg (sourced from Australia) will be assessed. This is intended to be a pivotal bioequivalence study.
- Trial name
- NCT01355068
- Testing
- Epanutin Infatabs (Phenytoin), Dilantin Infatabs (Phenytoin)
- Where
- Singapore
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Epilepsy, Complex Partial
A Treatment Use Protocol for Subjects Continuing on From the Open-label Extension 0601
This study is designed to provide ganaxolone to those patients deriving significant benefit from current treatment in protocol 1042-0601.
- Trial name
- 0602 (NCT01002820)
- Testing
- ganaxolone
- Where
- 7 sites in United States
- Volunteers
- 11 people
- Sponsor
- Marinus Pharmaceuticals
Refractory Partial Seizures
An add-on Study of E2007 in Patients With Refractory Partial Seizures Uncontrolled With Other Anti-epileptic Drugs (AEDs)
The purpose of this study is to explore the maximum tolerated dose of E2007 in Japanese patients with refractory partial seizures which are uncontrolled with other anti-epileptic drugs (AEDs).
- Trial name
- NCT00849212
- Testing
- E2007
- Where
- 9 sites in Japan
- Volunteers
- 30 people
- Sponsor
- Eisai Co., Ltd.
Epilepsy, Monotherapy
Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older
Compare efficacy and safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR) as monotherapy in newly or recently newly diagnosed subjects with a primary efficacy endpoint of 6-month seizure freedom.
- Trial name
- SP0993 (NCT01243177)
- Testing
- Lacosamide, Carbamazepine-Controlled Release
- Where
- 184 sites in United States, Australia and 27 more
- Volunteers
- 888 people
- Sponsor
- UCB BIOSCIENCES GmbH
Partial Epilepsy in Children and Adolescents
Eslicarbazepine Acetate (BIA 2 093) as Therapy for Refractory Partial Seizures in Children
The purpose of this study is to examine the efficacy and safety of Eslicarbazepine acetate (BIA 2-093) when given with other anti-epileptic drugs to treat children with partial seizures whose condition has not been controlled by…
- Trial name
- NCT00988156
- Testing
- Eslicarbazepine acetate (BIA 2-093), Eslicarbazepine acetate
- Where
- 91 sites in Austria, Bosnia and Herzegovina and 19 more
- Volunteers
- 304 people
- Sponsor
- Bial - Portela C S.A.
Epilepsy With Partial On-set Seizures
A Study of a Drug to be Used in Addition With Another Drug to Treat Adults With Uncontrolled Partial-onset Seizures
A study of a drug to be used in addition with another drug to treat adults with Uncontrolled Partial-onset Seizures
- Trial name
- NCT03116828
- Testing
- Eslicarbazepine acetate
- Where
- 55 sites in United States, Canada
- Volunteers
- 102 people
- Sponsor
- Sumitomo Pharma America, Inc.
Epilepsy
Open-Label Extension Study of the Phase 3 VRX-RET-E22-302 Double-Blind Trial. 115097
This Phase 3 trial is an open-label extension study of the placebo-controlled, double-blind VRX-RET-E22-302 trial. Patients who have completed the VRX-RET-E22-302 trial and who meet inclusion and exclusion criteria will be…
- Trial name
- NCT00310388
- Testing
- Retigabine (INN), Ezogabine (USAN)
- Where
- 67 sites in Australia, Belgium and 10 more
- Volunteers
- 376 people
- Sponsor
- GlaxoSmithKline
Epilepsy
A Placebo-controlled Study to Investigate Safety and Efficacy of BIA 2-093
The purpose of this study is to determine the efficacy of BIA 2 093 in the treatment of epileptic patients with refractory simple or complex partial seizures with or without secondary generalization.
- Trial name
- NCT02170077
- Testing
- BIA 2-093
- Where
- Portugal
- Volunteers
- 144 people
- Sponsor
- Bial - Portela C S.A.
Epilepsy, Partial Seizure Disorder
Comparative Study Of Pregabalin And Gabapentin As Adjunctive Therapy In Subjects With Partial Seizures
To compare the efficacy of pregabalin and gabapentin, as adjunctive therapy in subjects with partial seizures.
- Conditions
- Epilepsy, Partial Seizure Disorder, Epilepsies, Partial, Complex Partial Seizure Disorder
- Trial name
- NCT00537940
- Testing
- Pregabalin, Gabapentin
- Where
- 8 sites in Costa Rica, El Salvador and 2 more
- Volunteers
- 482 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Epilepsies, Partial
Vimpat® Added as Adjunctive Therapy to One Baseline Antiepileptic Drug
The purpose of this study is to systematically and prospectively collect data from patients with partial-onset seizures in routine clinical practice setting receiving adjunctive Vimpat®.
- Trial name
- VITOBA (NCT01098162)
- Where
- 113 sites in Germany
- Volunteers
- 576 people
- Sponsor
- UCB Pharma GmbH
Epilepsy
Conversion to Monotherapy Study With Keppra XR for Partial Seizures
The primary objective of this study is to assess the efficacy of two doses of Keppra XR compared with a historical control as the placebo, in the monotherapy treatment of partial onset seizures.
- Trial name
- NCT00419094
- Testing
- Keppra XR
- Where
- 45 sites in United States, Mexico and 2 more
- Volunteers
- 228 people
- Sponsor
- UCB Pharma
Epilepsy, Seizure Disorders
External Trigeminal Nerve Stimulation for Epilepsy
This study investigates a new therapy for epilepsy called Trigeminal Nerve Stimulation (TNS). TNS involves external electrical stimulation of sensory nerve located above the eyes and over the forehead.
- Trial name
- NCT01159431
- Testing
- Trigeminal Nerve Stimulation
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Olive View-UCLA Education & Research Institute
Epilepsy
An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam
The Sponsor wishes to develop brivaracetam as an anti-epileptic treatment in subjects 16 years and older with epilepsy. This study permits continued access to treatment for subjects who participated in a previous epilepsy study.
- Trial name
- NCT00761774
- Testing
- Brivaracetam
- Where
- 58 sites in United States, Australia and 9 more
- Volunteers
- 108 people
- Sponsor
- UCB Pharma
Epilepsy, Seizures
A Study of Intravenous Perampanel in Japanese Participants With Epilepsy
The purpose of the study is to evaluate the safety and tolerability of perampanel administered as a 30-minute intravenous infusion after switching from oral tablets (8 to 12 milligrams per day [mg/day]) as an adjunctive therapy…
- Trial name
- NCT03754582
- Testing
- Perampanel
- Where
- 13 sites in Japan
- Volunteers
- 21 people
- Sponsor
- Eisai Co., Ltd.
Epilepsy With Simple or Complex Partial Onset Seizures
Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs
This is an 18-week, double-blind, multicenter study with gradual conversion from previous antiepileptic therapy to eslicarbazepine acetate monotherapy in subjects with partial epilepsy.
- Trial name
- NCT00866775
- Testing
- Eslicarbazepine acetate
- Where
- 106 sites in United States, Canada
- Volunteers
- 193 people
- Sponsor
- Sumitomo Pharma America, Inc.
Epilepsy
Assessing The Long-Term Safety And To Explore The Long-Term Efficacy Of Zonisamide As Monotherapy In Newly Diagnosed Partial Seizures
The purpose of this study is to assess the long-term safety and tolerability and to explore the long-term efficacy of zonisamide as monotherapy treatment in subjects with newly diagnosed partial seizures.
- Trial name
- NCT00848549
- Testing
- Zonisamide, Carbamazepine
- Where
- 133 sites in Australia, Denmark and 18 more
- Volunteers
- 295 people
- Sponsor
- Eisai Inc.